Inhibition of Replication of Adenovirus by 6-diazo-5-oxo-L-norleucine (DON)
Klíčová slova:
6-diazo-5-oxo-L-norleucine, DON, adenovirus, Buffalo Green Monkey Kidney CellsAbstrakt
The antibiotic known as 6-diazo-5-oxo-L-norleucine (DON) inhibits the growth of several types of Gram-positive and Gram-negative bacteria. DON has also been demonstrated to inhibit the replication of poliovirus, respiratory syncytial virus, mumps, and herpes simplex virus in cultured eukaryotic cells. DON is an analogue of glutamine and inhibits the synthesis of glycoproteins and purine nucleotides in cells that are treated with the antibiotic. DON inhibits the aminotransferase enzyme that uses the amino group of glutamine to construct the precursor molecules of nucleotides and to convert fructose-6-phosphate into glucosamine for glycoprotein synthesis. DON does not inhibit the enzyme activity of Buffalo green monkey kidney (BGMK) cells at concentrations as high as 2,500 µg/ml. At a concentration of 5 µg/ml, DON inhibits the replication of adenovirus in BGMK cells by 71.7% and at a concentration of 10 µg/ml, DON inhibits the replication of adenovirus by 92%. Addition of excess glutamine and nucleosides partially reverses the inhibition of adenovirus replication by DON while the addition of excess glucosamine has no effect on the inhibition of virus replication by DON. These results suggest that DON inhibits the replication of adenovirus by inhibiting the metabolism of glutamine and nucleosides during adenovirus replication but not glycoprotein synthesis. Keywords: 6-diazo-5-oxo-L-norleucine (DON), adenovirus, Buffalo Green Monkey Kidney (BGMK) cellsCite this Article Goldstein G, Harden JL. Inhibition of Replication of Adenovirus by 6-diazo-5-oxo-L-norleucine (DON). Research & Reviews: Journal of Microbiology and Virology. 2016; 6(3): 31–37p.Publikováno
Číslo
Sekce
Licence
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
· I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
· I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
· I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
· I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
_______________
We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |